Accueil   Diary - News   All news THERANEXUS PUBLISHES ITS CASH POSITION AS OF 30 SEPTEMBER 2021 AND PRESENTS ITS PROGRESS REPORT

THERANEXUS PUBLISHES ITS CASH POSITION AS OF 30 SEPTEMBER 2021 AND PRESENTS ITS PROGRESS REPORT

 

 

Lyon, 19 October 2021 – Theranexus, a biopharmaceutical company innovating in the treatment of neurological diseases and pioneer in the development of drug candidates modulating the interaction between neurons and glial cells, today announces its cash position as at 30 September 2021.

 

Total available funds on 30 September 2021 stood at €12.5 M, compared with €13.5 M on 30 June 2021. The Company's cash position is relatively stable and provides financial visibility for the next 18 months in accordance with its set targets. During the second half of 2021, the Company should also benefit from the 2020 Research Tax
Credit (CIR) for a sum of €1.0 M, and from Bpifrance funding for an amount of €1.0 M in connection with the Neurolead project.

 


Thierry Lambert, Chief Financial Officer of Theranexus, made the following comment: "The Company's cash position of €12.5 M on 30 September 2021 illustrates controlled cash consumption and is consistent with our objective to maintain financial visibility for at least the next 18 months."

 

Read the press release